Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 05, 2021

SELL
$11.94 - $16.09 $1,194 - $1,609
-100 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$14.36 - $20.93 $1,436 - $2,093
100 New
100 $2,000
Q1 2021

May 24, 2021

SELL
$18.19 - $33.25 $1,819 - $3,325
-100 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$15.7 - $20.84 $1,570 - $2,084
100 New
100 $2,000
Q4 2019

Feb 04, 2020

SELL
$9.73 - $19.31 $642 - $1,274
-66 Closed
0 $0
Q1 2019

May 20, 2019

SELL
$15.53 - $19.75 $7,050 - $8,966
-454 Reduced 87.31%
66 $1,000
Q4 2018

Feb 15, 2019

SELL
$15.58 - $28.41 $55,760 - $101,679
-3,579 Reduced 87.31%
520 $9,000
Q2 2018

Jul 27, 2018

BUY
$27.78 - $38.53 $583 - $809
21 Added 0.51%
4,099 $123,000
Q1 2018

Apr 23, 2018

BUY
$27.78 - $35.19 $113,286 - $143,504
4,078 New
4,078 $0

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $82.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Advisory Services Network, LLC Portfolio

Follow Advisory Services Network, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Services Network, LLC with notifications on news.